Baird Medical Investment Holdings AI Stock Analysis
Want to see BDMD full AI Analyst Report?
Baird Medical Investment Holdings (BDMD) AI Stock Analysis
Baird Medical Investment Holdings
(NASDAQ:BDMD)
BDMD scores at the bottom of the range. The dominant factor is a sharp fundamental deterioration: a 29% revenue decline, a $27.3M net loss that erased roughly two years of prior earnings, rising leverage, and a shrinking equity base. Compounding this is a multi-year inability to generate positive operating or free cash flow, which questions the durability of the business model and points to potential financing or dilution risk. Technicals reinforce the caution, with the stock trading far below every major moving average and momentum still negative. Valuation provides no offset — earnings are negative and there is no dividend. Any improvement in the score would require evidence that the revenue decline is reversible, the cost base can be right-sized, and cash burn can be eliminated.
Baird Medical Investment Holdings (BDMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.91M
- Dividend Yield
- ―
- Average Volume (3M)
- 15.20M
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- -0.32
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 146
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Baird Medical Investment Holdings Business Overview & Revenue Model
Company Description
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive managemen...
Baird Medical Investment Holdings Financial Statement Overview
Summary
Financials are the weakest part of the story. The income statement (score 22) shows a severe 2025 reversal: revenue fell ~29% to $22.5M and the company swung to a $27.3M net loss (-121% net margin) despite gross margins near 84%, indicating a cost structure badly out of line with sales. The balance sheet (score 40) still offers a modest cushion — $31.4M equity and manageable $19.3M debt — but equity is eroding, debt-to-equity has climbed to 0.62, and ROE has turned to -87%. Cash flow (score 28) is the chronic problem: operating and free cash flow have been negative for four straight years, even during reportedly profitable periods, raising earnings-quality concerns and the risk of future financing or dilution.
Income Statement
22NegativeBalance Sheet
40NegativeCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.49M | 22.54M | 37.04M | 31.46M | 35.09M | 27.72M |
| Gross Profit | 20.97M | 18.88M | 32.65M | 27.23M | 28.04M | 23.18M |
| EBITDA | -13.02M | -24.53M | 16.17M | 13.24M | 16.29M | 14.16M |
| Net Income | -15.95M | -27.28M | 12.45M | 10.55M | 12.57M | 11.68M |
Balance Sheet | ||||||
| Total Assets | 73.85M | 69.70M | 77.96M | 56.71M | 42.62M | 26.12M |
| Cash, Cash Equivalents and Short-Term Investments | 289.08K | 178.32K | 2.97M | 1.63M | 1.91M | 3.44M |
| Total Debt | 14.22M | 19.30M | 20.88M | 9.90M | 7.44M | 2.93M |
| Total Liabilities | 39.22M | 38.48M | 38.20M | 21.00M | 16.84M | 10.26M |
| Stockholders Equity | 34.77M | 31.37M | 39.66M | 35.75M | 25.93M | 5.20M |
Cash Flow | ||||||
| Free Cash Flow | 4.31M | -1.39M | -9.17M | -3.66M | -5.47M | 3.87M |
| Operating Cash Flow | 4.31M | -1.34M | -6.31M | -1.02M | 485.97K | 5.26M |
| Investing Cash Flow | 2,295 | -42.31K | -2.85M | -2.64M | -5.92M | -1.39M |
| Financing Cash Flow | -6.44M | -1.39M | 10.72M | 3.46M | 4.41M | -1.93M |
Baird Medical Investment Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDMD, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.61, and below the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 21.53 is Positive, neither overbought nor oversold. The STOCH value of 17.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDMD.
Baird Medical Investment Holdings Risk Analysis
Baird Medical Investment Holdings disclosed 83 risk factors in its most recent earnings report. Baird Medical Investment Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBaird Medical Investment Holdings Peers Comparison
Overall Rating
APYX53Neutral
ICCM42Neutral
VANI41Neutral
XTNT41Neutral- BDMD37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| APYX | 53Neutral | $118.37M | -14.21 | -70.78% | ― | 24.35% | 46.90% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ICCM | 42Neutral | $2.50M | -0.11 | -174.26% | ― | 41.62% | 20.47% |
| VANI | 41Neutral | $91.11M | -3.16 | -161.39% | ― | ― | 25.92% |
| XTNT | 41Neutral | $38.12M | -3.31 | -23.45% | ― | -14.27% | -132.84% |
| BDMD | 37Underperform | $2.90M | -0.16 | -48.23% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BDMD | Baird Medical Investment Holdings Ltd | 0.09 | -1.20 | -93.02% | |
| APYX | Apyx Medical | 2.81 | -1.22 | -30.27% | |
| VANI | Vivani Medical, Inc. | 1.01 | -0.46 | -31.29% | |
| XTNT | Xtant Medical Holdings Inc | 0.27 | -0.41 | -60.32% | |
| ICCM | Icecure Medical Ltd. | 0.73 | -20.53 | -96.57% |
Baird Medical Investment Holdings Corporate Events
Baird Medical Reports Nasdaq Minimum Bid Price Deficiency
Baird Medical Investment Holdings develops minimally invasive ablation technologies for solid tumors, with a primary focus on microwave ablation treatment for benign thyroid nodules in the U.S. and an expanding global commercial presence. Its portfol...
Baird Medical Secures Senior Convertible Note Financing Backed by U.S. Assets
On September 24, 2026, Baird Medical Investment Holdings entered into a Securities Purchase Agreement with an institutional investor for a senior 8% original issue discount convertible promissory note with a principal amount of about $4.35 million, r...
Baird Medical Reports Interim H1 2026 Results and Strengthens U.S. Filings
On September 30, 2026, Baird Medical Investment Holdings furnished a Form 6-K to the U.S. Securities and Exchange Commission, providing unaudited interim condensed consolidated financial statements and management’s discussion and analysis for the six...
Baird Medical Swings to Profit on 25% Revenue Surge in First Half of 2026
On September 3, 2026, Baird Medical reported preliminary unaudited financial results for the six months ended June 30, 2026, showing that revenue rose 24.6% year over year to about $9.9 million, driven largely by sales growth outside the PRC, particu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026